Stoke Therapeutics (NASDAQ:STOK) Director Edward Md Kaye Sells 1,066 Shares

Stoke Therapeutics, Inc. (NASDAQ:STOK) Director Edward Md Kaye sold 1,066 shares of the company’s stock in a transaction on Tuesday, December 2nd. The shares were sold at an average price of $29.78, for a total value of $31,745.48. Following the sale, the director directly owned 52,375 shares of the company’s stock, valued at approximately $1,559,727.50. This represents a 1.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Stoke Therapeutics Trading Up 3.9%

Shares of STOK traded up $1.15 during midday trading on Wednesday, hitting $30.96. The stock had a trading volume of 665,349 shares, compared to its average volume of 1,025,254. The business has a 50-day simple moving average of $28.74 and a two-hundred day simple moving average of $19.61. The firm has a market cap of $1.77 billion, a P/E ratio of 46.21 and a beta of 1.14. Stoke Therapeutics, Inc. has a fifty-two week low of $5.35 and a fifty-two week high of $38.69.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.11). Stoke Therapeutics had a net margin of 19.73% and a return on equity of 13.28%. The firm had revenue of $10.63 million during the quarter, compared to analysts’ expectations of $6.06 million. On average, analysts expect that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently weighed in on STOK. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Stoke Therapeutics in a research report on Monday. Wedbush increased their price target on shares of Stoke Therapeutics from $22.00 to $32.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 5th. Needham & Company LLC lifted their price objective on shares of Stoke Therapeutics from $22.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, October 10th. JPMorgan Chase & Co. upped their price objective on shares of Stoke Therapeutics from $15.00 to $25.00 and gave the stock a “neutral” rating in a report on Monday, November 3rd. Finally, BTIG Research restated a “buy” rating and set a $39.00 target price on shares of Stoke Therapeutics in a report on Wednesday, November 5th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, Stoke Therapeutics currently has an average rating of “Buy” and a consensus price target of $31.00.

Institutional Investors Weigh In On Stoke Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Generali Investments Management Co LLC acquired a new position in shares of Stoke Therapeutics in the 3rd quarter valued at $41,000. BNP Paribas Financial Markets increased its stake in Stoke Therapeutics by 66.2% in the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock valued at $48,000 after acquiring an additional 1,668 shares during the period. Tower Research Capital LLC TRC raised its position in Stoke Therapeutics by 461.0% in the second quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock worth $50,000 after purchasing an additional 3,591 shares in the last quarter. AlphaQuest LLC acquired a new position in Stoke Therapeutics in the first quarter worth about $72,000. Finally, US Bancorp DE lifted its stake in Stoke Therapeutics by 9,743.9% during the first quarter. US Bancorp DE now owns 11,222 shares of the company’s stock worth $75,000 after purchasing an additional 11,108 shares during the period.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.